- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
D Rating for PSA Test to Screen for Prostate Cancer
The USPSTF have continued to give screening using prostate-specific antigen (PSA) a D rating, meaning that they recommend against it. Their argument is that the harms outweigh the benefits, and at best, the benefits are small from 10 to 14 years after screening has commenced.
Many people will object to this recommendation, believing that many lives have been saved as a result of screening. The USPSTF's points are:
• First, the screening process results in pain, suffering, and a small risk for other complications.
• Second, there is a psychological consequence of receiving a false-positive test.
• Third, many of those men who are diagnosed with cancer will receive a treatment that was unnecessary, because there is still a difficulty distinguishing prostate cancers that are life-threatening from those that are indolent.
Read the commentary here: http://bit.ly/UOrZ6R
Source: Medscape
Link to the USPSTF recommendation: http://1.usa.gov/UOrBW5
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
